ArticleJournal of translational medicine2026
ZNF692 promotes the proliferation, invasion and migration of prostate cancer cells by activating the NF-κB signaling pathway.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProstate cancer (PCa) recurrence, progression, and drug resistance remain critical clinical challenges. Bioinformatics analyses have implicated ZNF692 in PCa initiation and progression. This study aimed to investigate its impact on PCa biological behavior and underlying mechanisms, potentially identifying novel diagnostic and therapeutic targets.
methodsZNF692 protein expression was detected in 75 paired PCa and adjacent normal tissues using immunohistochemical (IHC) SP staining, and its correlation with clinicopathological features was analyzed. RT-qPCR and Western blot (WB) were used to detect the expression of ZNF692 mRNA and protein in 5 PCa cell lines (PC3, DU145, LNCaP, 22RV1, C4-2) and normal prostate cell line (RWPE-1). ZNF692 knockdown and overexpression PCa cell lines were established by lentivirus transfection. Cell proliferation, migration and invasion abilities were detected by CCK-8, Colony Formation Assay, Scratch assay and Transwell assay; in vivo effects were verified by nude mouse subcutaneous tumor formation and tail vein lung metastasis models. Differentially expressed proteins were screened by proteomics sequencing, and pathway enrichment was analyzed by Kyoto Encyclopedia of Genes and Genomes (KEGG); WB was used to verify the effect of ZNF692 on the core and downstream proteins of The nuclear factor-kappa B (NF-κB) signaling pathway; functional recovery experiments (LPS activator/SN50 inhibitor) confirmed the pathway dependence.
resultsZNF692 was highly expressed in prostate cancer tissues and was positively correlated with the clinical pathological stage. The expression of ZNF692 mRNA and protein in prostate cancer cell lines was significantly increased. Overexpression of ZNF692 promotes the proliferation, migration and invasion of prostate cancer cells, while knockdown inhibits them; in vivo experiments also confirmed its tumor-promoting effect. Proteomic sequencing identified 1109 differentially expressed proteins, and KEGG analysis showed that the NF-κB signaling pathway-a classic cancer-related pathway-was significantly enriched. WB confirmed that ZNF692 can activate the core and downstream proteins of the NF-κB signaling pathway. Functional restoration experiments demonstrated that ZNF692 functions through the NF-κB pathway (LPS can partially restore the inhibitory effect of knocking down ZNF692, and SN50 can partially reverse the promoting effect of overexpressing ZNF692).
conclusionZNF692 may promote cell proliferation, migration and invasion of prostate cancer cells by activating the NF-κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.